Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 12

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 12
---
 TELO Common Stock. TELO will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. In addition to these proxy materials, TELO’s directors and employees may also solicit proxies in person, by telephone or by other means of communication.

Questions Relating to the Merger

Q: What is the Merger?

TELOPHARM Acquisition, Inc., a Delaware corporation and wholly owned subsidiary of TELO (“Merger Sub”), and TELI Pharmaceuticals, Inc., a Delaware corporation (“TELI”), entered into the Agreement and Plan of Merger and Reorganization on November 20, 2025 (the “Merger Agreement”). The Merger Agreement, as it may be further amended from time to time, contains the terms and conditions of the proposed transaction among TELO, Merger Sub and TELI. Under the Merger Agreement, Merger Sub will merge with and into TELI, with TELI surviving as a wholly owned subsidiary of TELO (the “Merger”).

At the Effective
Time, each outstanding share of TELI Common Stock will be converted into the right to receive such number of shares of Telomir Common
Stock as is calculated based on the Exchange Ratio, but in no instance will the amount of TELO Common Stock issued be greater than the
number of outstanding TELO Common Stock as-of the closing date of the Merger. The Exchange Ratio is calculated using the relative company
valuations of each of TELO and TELI, as determined by Moore (as further described herein). It is expected that shareholders of TELO will
receive one share of TELI Common Stock for each share of TELI Common Stock held (the “Merger Share Consideration”). The TELI
Common Stock issued as the consideration will not be registered for trading under the Securities Act.

In addition to
the Merger Consideration, Erez Aminov and Bayshore Trust, shareholders of TELI, hold 4,250,000 and 10,000,000 warrants, respectively,
to purchase TELI Common Stock (the “Warrants”). The Warrants are exercisable upon FDA acceptance of an Investigational New
Drug (IND) application for Telomir at $2.00 per share, for a period of 10-years. At Closing, the Warrants will be converted to warrants
to purchase Telomir Common Stock at